Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in IgG4-Related Disease
NCT03669861Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in IgG4-related disease (IgG4-RD), sponsored by Massachusetts General Hospital. Primary endpoint: Treatment Response (Complete Remission) at 24 weeks. Started Nov 2018; status: completed.
02
Drugs
abatacept
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT03669861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669861.